Miguel Gil-Gil
Bellvitge University Hospital
92 Papers
114 Citations
Miguel Gil-Gil is an academic researcher from Bellvitge University Hospital. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 15, co-authored 61 publications. Previous affiliations of Miguel Gil-Gil include University of Barcelona.
Chat about Author
Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Erica L. Mayer,Amylou C. Dueck,Miguel Martín,G. Rubovszky,Harold J. Burstein,Meritxell Bellet-Ezquerra,Kathy D. Miller,Nicholas Zdenkowski,Eric P. Winer,Georg Pfeiler,Matthew Bidwell Goetz,Manuel Ruiz-Borrego,Daniel G. Anderson,Zbigniew Nowecki,Sibylle Loibl,Stacy L. Moulder,Alistair Ring,Florian Fitzal,Tiffany A. Traina,Arlene Chan,Hope S. Rugo,Julie Lemieux,Fernando Henao,Alan P. Lyss,Silvia Antolin Novoa,Antonio C. Wolff,Marcus Vetter,Daniel Egle,Patrick G. Morris,Eleftherios P. Mamounas,Miguel Gil-Gil,Aleix Prat,Hannes Fohler,Otto Metzger Filho,Magdalena Schwarz,Carter Dufrane,Debora Fumagalli,Kathy Puyana Theall,D. Lu,Cynthia Huang Bartlett,Maria Koehler,Christian Fesl,Angela DeMichele,Michael Gnant +43 more
TL;DR: The PALLAS trial as discussed by the authors investigated whether the addition of 2 years of palbociclib to adjuvant endocrine therapy improves invasive disease-free survival over endocrine treatment alone in patients with hormone-receptor-positive, HER2-negative, early stage breast cancer.
223
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Juan M. Sepúlveda-Sánchez,M.A. Vaz,Carmen Balana,Miguel Gil-Gil,Gaspar Reynes,Oscar Gallego,Maria Martinez-Garcia,Elena Vicente,María Quindós,R. Luque,Ana Ramos,Yolanda Ruano,Pedro Pérez-Segura,Manuel Benavides,Pilar Sánchez-Gómez,Aurelio Hernández-Laín +15 more
TL;DR: Dacomitinib has a limited single-agent activity in recurrent glioblastoma with EGFR amplification and the detailed molecular characterization of the 4 patients with response in this trial can be useful to select patients who could benefit from dacomItinib.
Bevacizumab for the Treatment of Glioblastoma
Miguel Gil-Gil,Carlos Mesia,Montserrat Rey,Jordi Bruna +3 more
- 06 Jun 2013
TL;DR: The mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile, its potential side effects and complications and its place in therapy are reviewed.
96
SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).
Maria Martinez-Garcia,J. Álvarez-Linera,Cristina Carrato,L. Ley,R. Luque,X. Maldonado,M. Martínez-Aguillo,L. M. Navarro,M. A. Vaz-Salgado,Miguel Gil-Gil +9 more
TL;DR: The treatment for recurrent GB is not well defined, and decision-making is usually based on prior strategies as well as several clinical and radiological factors.